Xigris 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

xigris

eli lilly nederland b.v. - drotrekogín alfa (aktivovaný) - sepsis; multiple organ failure - antitrombotické činidlá - xigris je indikovaný na liečbu dospelých pacientov s ťažkou sepsou s viacnásobným zlyhávaním orgánov, ak sa pridávajú do najlepšej štandardnej starostlivosti. použitie lieku xigris sa má zvážiť hlavne v situáciách, kedy môže byť liečba zahájená do 24 hodín po nástupe poruchy orgánu (ďalšie informácie nájdete v časti 5.

MEDORISPER 1 mg 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medorisper 1 mg

medochemie ltd., cyprus - risperidón - 68 - antipsychotica (neuroleptica)

MEDORISPER 2 mg 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medorisper 2 mg

medochemie ltd., cyprus - risperidón - 68 - antipsychotica (neuroleptica)

MEDORISPER 3 mg 斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medorisper 3 mg

medochemie ltd., cyprus - risperidón - 68 - antipsychotica (neuroleptica)

Silodosin Recordati 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

silodosin recordati

recordati ireland ltd - silodozín - hyperplázia prostaty - urologicals, alfa-adrenoreceptor antagonisty - liečbu známok a príznakov benígna hyperplázia prostaty (bph) u dospelých mužov.

Lysini hydrochloridum 40 000 mg, D,L- Methioninum 30 000 mg, Retinoli acetas 400 000 IU, Thiaminum 50 mg, Riboflavinum 80 mg, Pyridoxini hydrochloridum 70 mg, Cyanocobalaminum 0,5 mg, Acidum nicotinicum 600 mg, Biotinum 10 mg, Cholini chloridum 12 000 mg, Calcii pantothenas 350 mg, Colecalciferolum 60 000 IU, Tocoferoli alfa acetas 400 mg, Menadionum 40 mg, Calcii hydrogenphosphas 250 000 mg, Natrii chloridum 25 000 mg, Ferrosi sulfas 3 200 mg, Cupri sulfas 130 mg, Zinci oxidum 1 200 mg, Mangani carbonas 1 000 mg, Kalii iodidum 10 mg, Cobalti chloridum 8 mg, Bioplex ferrosi 1 800 mg, Bioplex cupri 150 mg, Bioplex zinci 1 600 mg, Bioplex mangani 1 200 mg, Bioplex cobalti 30 mg, Selplex 50 (Selenis) 3 000 mg, Antioxidanti 200 mg, Vehiculum ad 1,00 kg. 斯洛伐克 - 斯洛伐克文 - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

lysini hydrochloridum 40 000 mg, d,l- methioninum 30 000 mg, retinoli acetas 400 000 iu, thiaminum 50 mg, riboflavinum 80 mg, pyridoxini hydrochloridum 70 mg, cyanocobalaminum 0,5 mg, acidum nicotinicum 600 mg, biotinum 10 mg, cholini chloridum 12 000 mg, calcii pantothenas 350 mg, colecalciferolum 60 000 iu, tocoferoli alfa acetas 400 mg, menadionum 40 mg, calcii hydrogenphosphas 250 000 mg, natrii chloridum 25 000 mg, ferrosi sulfas 3 200 mg, cupri sulfas 130 mg, zinci oxidum 1 200 mg, mangani carbonas 1 000 mg, kalii iodidum 10 mg, cobalti chloridum 8 mg, bioplex ferrosi 1 800 mg, bioplex cupri 150 mg, bioplex zinci 1 600 mg, bioplex mangani 1 200 mg, bioplex cobalti 30 mg, selplex 50 (selenis) 3 000 mg, antioxidanti 200 mg, vehiculum ad 1,00 kg.

Vegzelma 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

vegzelma

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. Ďalšie informácie o stave receptora ľudského epidermálneho rastového faktora 2 (her2) nájdete v časti 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. Ďalšie informácie o stave her2 nájdete v časti 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Opfolda 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

opfolda

amicus therapeutics europe limited - miglustat - glykogénová choroba typu ii - ostatné produkty tráviaceho traktu a metabolizmu - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

Ribavirin Teva Pharma B.V. 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

ribavirin teva pharma b.v.

teva b.v. - ribavirin - hepatitída c, chronická - antivirotiká na systémové použitie - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 a 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 a 5.

Rebetol 欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

rebetol

merck sharp and dohme b.v - ribavirin - hepatitída c, chronická - antivirals for systemic use, antivirals for treatment of hcv infections - rebetol je indikovaný v kombinácii s inými liekmi na liečbu chronickej hepatitídy c (chc) u dospelých. rebetol je indikovaný v kombinácii s inými liekmi na liečbu chronickej hepatitídy c (chc) pre pediatrických pacientov (deti od 3 rokov veku a starších a dospievajúcich), ktoré predtým neboli liečení a bez pečene decompensation.